Authors: David Kachaner, Pierre Génin, Emmanuel Laplantine and Robert Weil

David Kachaner

Institut Pasteur; Unité de Signalisation Moléculaire et Activation Cellulaire; CNRS URA 2582; Paris, France; Université Pierre et Marie Curie; Cellule Pasteur UPMC; Paris, France
These authors contributed equally to this work.

Pierre Génin

Institut Pasteur; Unité de Signalisation Moléculaire et Activation Cellulaire; CNRS URA 2582; Paris, France
These authors contributed equally to this work.

Emmanuel Laplantine

Institut Pasteur; Unité de Signalisation Moléculaire et Activation Cellulaire; CNRS URA 2582; Paris, France

Robert Weil

Corresponding author: rweil@pasteur.fr
Institut Pasteur; Unité de Signalisation Moléculaire et Activation Cellulaire; CNRS URA 2582; Paris, France

Abstract:
This review highlights recent advances in our understanding of the mechanisms of Optineurin (Optn) action and its implication in diseases. Optn has emerged as a key player regulating various physiological processes, including membrane trafficking, protein secretion, cell division and host defense against pathogens. Furthermore, there is growing evidence for an association of Optn mutations with human diseases such as primary open-angle glaucoma, amyotrophic lateral sclerosis and Paget’s disease of bone. Optn functions depend on its precise subcellular localization and its interaction with other proteins. Here, we review the mechanisms that allow Optn to ensure a timely and spatially coordinated integration of different physiological processes and discuss how their deregulation may lead to different pathologies.

Received: April 13, 2012; Accepted: May 30, 2012

Preview: